After a twitching pinky finger led to a diagnosis of young-onset Parkinson's disease, Keith Krehbiel, then 42, stopped at a bookstore on the way home to learn more about the progressive ...

The following table presents notable drug approvals of February 2025. Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive ...

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...

The company expects operating earnings (loss) between $(15) million and $10 million. Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced ...

Cantor Fitzgerald downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. See what stocks are receiving strong buy ratings from top-rated analysts. Filter ...

Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer. In a large cohort of ...

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO ...